Professor Ed Vital discusses two key publications covered on the Lupus Forum in December. his podcast reviews data from a randomised, double-blind, placebo-controlled Phase Ib/IIa trial of the anti-CD38 monoclonal antibody CM313 in adults with systemic lupus erythematosus (SLE), focusing on safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy. The episode also examines predictors of damage accrual by organ domain in SLE, highlighting factors associated with long-term disease outcomes. If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/
All content for The Lupus Forum is the property of The Lupus Forum and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Professor Ed Vital discusses two key publications covered on the Lupus Forum in December. his podcast reviews data from a randomised, double-blind, placebo-controlled Phase Ib/IIa trial of the anti-CD38 monoclonal antibody CM313 in adults with systemic lupus erythematosus (SLE), focusing on safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy. The episode also examines predictors of damage accrual by organ domain in SLE, highlighting factors associated with long-term disease outcomes. If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/
Professor Ed Vital discusses two key publications covered on the Lupus Forum in December. his podcast reviews data from a randomised, double-blind, placebo-controlled Phase Ib/IIa trial of the anti-CD38 monoclonal antibody CM313 in adults with systemic lupus erythematosus (SLE), focusing on safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy. The episode also examines predictors of damage accrual by organ domain in SLE, highlighting factors associated with long-term disease outcomes. If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/
Professor Richard Furie and Doctor Guillermo J. Pons-Estel review two key publications covered on the Lupus Forum in November. This podcast reports data from a multicentre, randomised, double-blind, placebo-controlled trial evaluating low-dose belimumab in patients with systemic lupus erythematosus (SLE), with a focus on disease flare prevention. The episode also reports findings on the efficacy and safety of allogeneic CD19 CAR NK-cell therapy in SLE, based on a case series conducted in China in patients with mild disease activity. If you are interested in the papers discussed, head on over to the Lupus Forum today!
Professor Vibeke Strand highlights the emerging treatments in SLE and LN. This podcast reports the efficacy and safety results of a Phase 3 trial of telitacicept at a dose of 160mg weekly as compared with PBO in Chinese persons with active SLE. The efficacy and safety of SC secukinumab 300mg compared with PBO, in combination with the SoC, in patients with active LN is also reported.
If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/
Join Professor Ed Vital, Dr Guillermo J. Pons-Estel, Professor Richard Furie and Professor Chris Edwards on the Lupus Forum for their discussion of the recent webinar “Early use of advanced therapies in lupus”. Watch them discuss key highlights from the webinar, including limitations of SoC, insights from clinical trials and strategies for early intervention with advanced therapies.
Visit www.lupusforum.com to access the full webinar content, including detailed slide materials from Dr Guillermo J. Pons-Estel, Professor Richard Furie and Professor Chris Edwards.
Join Professors Ed Vital and Maria Dall'Era as they review their highlights of the recent ACR 2025 congress, watch them discuss their abstracts and highlight key information.
Join Professor Chris Edwards and Doctor Alice Mason as they discuss EULAR recommendations for a core dataset in SLE and efficacy and safety of upadacitinib as a monotherapy or combination with elsubrutinib for SLE. This podcast provides a valuable framework for guiding therapeutic decisions in SLE, and also supporting clinical care, translational/observation research.
If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/
Join Professors Ed Vital and Maria Dall'Era as they preview what they are most looking forward to this ACR, introducing some of the top abstracts and posters we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.
Professor Eric Morand highlights the therapeutic strategies and emerging treatments in SLE and LN. This podcast provides a valuable framework for guiding therapeutic decisions for rare SLE manifestations where the available recommendations might be insufficient or inapplicable. The efficacy, PK and safety of iscalimab versus placebo as add-on to SoC therapy in patients with biopsy-proven active proliferative LN is also reported.
If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/
Join Professor Brad Rovin for an expert-led discussion focused on emerging therapies and renal outcomes in LN. This podcast will provide an overview of the effect of long-term voclosporin treatment on renal histology in patients with active LN with repeat renal biopsies, and explore how BCMA-targeted CAR T-cell therapy can effectively induce disease remission in refractory LN.
If you are interested in the papers discussed, head on over to the Lupus Forum today!
Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/
Join Professors Ed Vital and Maria Dall’Era, and Doctor Guillermo J. Pons-Estel for an expert-led discussion focusing on the latest ACR 2025 SLE Guidelines. This podcast provides an overview of the latest treatment recommendations, as well as ungraded, consensus-based good practice statements that are applicable to children and adults with SLE.
If you are interested in the paper discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/
Join Professors Ed Vital and Michelle Kahlenberg as they delve into the role of the cGAS pathway in systemic lupus erythematosus (SLE). This engaging discussion covers the pathway’s relevance in disease, recent clinical trial updates on cGAS inhibitors, and their potential role in the future treatment of SLE.
Join Professor Ed Vital, and Doctors Reuben Benjamin, Chris Wincup, and Marc Scherlinger on the Lupus Forum in their discussion on the recent webinar “CAR-T and CAR-NK therapies: Are they the future of lupus treatment?”. Watch them discuss key highlights from the webinar including the potential of CAR-T and CAR-NK therapies as transformative treatments for lupus. Highlighting the mechanisms, applications, and the challenges of this treatment. Visit www.lupusforum.com to access the full webinar content, including detailed slide materials from Doctors Reuben Benjamin, Chris Wincup, and Marc Scherlinger.
Join Professors Ed Vital and Chris Edwards as they review their highlights of the recent EULAR 2025 congress, watch them discuss their abstracts and highlight key information.
Our Steering Committee Member Professor Maria Dall’Era is joined by Professor Vibeke Strand in the latest Lupus Forum podcast. Together they discuss the efficacy of belimumab treatment in patients with SLE. They will also discuss the impact of long-term anifrolumab treatment on patients’ perceived health status and health-related quality of life.
If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/
Professor Ed Vital discusses two key publications covered on the Lupus Forum in December. his podcast reviews data from a randomised, double-blind, placebo-controlled Phase Ib/IIa trial of the anti-CD38 monoclonal antibody CM313 in adults with systemic lupus erythematosus (SLE), focusing on safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy. The episode also examines predictors of damage accrual by organ domain in SLE, highlighting factors associated with long-term disease outcomes. If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/
